Lexaria Receives US$3,817,643 From Warrant Exercises | NasdaLexaria Receives US$3,817,643 From Warrant Exercises | Nasdaq I’m forwarding you updated presentation and upcoming studies to come, one more antiviral in August and 2
nd human clinical first week of September which is 3 doses a day versus first phase of only 1 dose over 3 hour small test which succeeded in lowering blood pressure versus the standard CBD sold on the shelves which have poor bioavailability ...
Dehydratech patented technology also works for synthetic antivirals as early studies have indicated ..
PowerPoint Presentation (d1io3yog0oux5.cloudfront.net) Also like to note the B2B clients look to doing significant nationwide expansion as per expectation announced last week press release
DehydraTECH-Enabled Consumer Products Now Available in Over 7,000 Stores | Nasdaq New B2b partnerships completed for huge consumer CBD products across USA as per Hillstreet and Dehydr8 B2B B2C
Hill Street Beverage Company Inc. Announces Major New Licensing Partnership to Expand Cutting-Edge DehydraTECH(TM) Technology into US Cannabis Markets | Nasdaq Update on antiviral market which in my opinion is significant for big pharma to now look at the technology has it improve the efficacy in a big way as per press below
Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy | Nasdaq Thank you